Right from pioneering niche marketing in India to earning the sobriquet of 'The Company with the Most First Launches,' Torrent Pharma has established itself as a major player in the Indian Pharma arena. We have well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). Our vast field force of more than 5500 personnel cater to 1.70 Lakh Doctors across the country. Torrent Pharma has a strong domestic presence in India with modern manufacturing facilities and cutting edge R & D Center. Revenues in India was Rs. 4,984 Cr. in 2022 – 2023. Torrent Pharma reaches the target market segments through 27 sales divisions with a wide customer coverage through 5500+ stockists and 59000 retailers serviced through 23 distribution centres across India.
In 2019, Torrent & Glenmark inked licensing agreement for co-marketing of Remogliflozin Etabonate in India. To address the Covid-19 therapeutic needs, Torrent Pharma introduced MSD and Ridgeback’s molnupiravir under the brand name Molnutor® in India in 2021, while it also entered into Voluntary Licensing Agreement with Lilly to manufacture and distribute Baricitinib for Covid-19 in India.
In 2022, Torrent Pharma acquired four brands "Styptovit-E", "Finast", "Finast-T", and "Dynapress" from Dr. Reddy's Laboratories Ltd. Also, the Company entered into licensing agreement with Medicine Patent Pool to manufacture and commercialise generic version of Pfizer Oral COVID-19 Treatment. For the anti-diabetic drug, Torrent Pharma entered into co-marketing partnership with Boehringer Ingelheim India Private Limited. Towards the end of 2022, Torrent Pharma acquired Curatio Healthcare to strengthen its presence in fast growing dermatology segment.
With Unichem's and Curatio domestic business acquisitions, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 6 in the IPM.